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Available online 17 February 2014Highly pathogenic avian influenza virus (HPAI) and virulent forms of avian paramyxovirus-1
(APMV-1) cause serious illnesses in domestic poultry, both of which are reportable to the World
Organization of Animal Health (OIE). The clinical presentation of avian influenza (AI) andAPMV-1
infections are difficult to differentiate, emphasizing the importance of rapid and sensitive
serologic assays that are able to distinguish them. Currently, a variety of serological assays are
used for the serologic diagnosis of both diseases, but these assays are not used in multiplex
formats. In this study, development of a duplex fluorescent microsphere immunoassay (FMIA)
based on Luminex xMAP Technology is described. The assay employs MagPlex magnetic
microspheres that are covalently coated with recombinant avian influenza virus nucleoprotein
and APMV-1 nucleocapsid antigens produced in a baculovirus insect cell expression system. The
assay is able to detect AIV antibodies against all existing hemagglutinin (H1–H16) subtypes and
simultaneously detect antibodies against APMV-1. In the process of this assay development
different bead coupling conditions were compared. The assay has the capability of detecting
serum antibodies from chickens and turkeys and optimization was accomplished by using 2462
chicken and 446 turkey field and experimental sera and had a comparable detection capability
with currently used assays in the laboratory. Assay threshold values were calculated with
Receiver Operating Characteristic Analysis (ROC) in non-parametric analysis due to a highly
skewed data distribution; this analysis resulted in AIV nucleoprotein relative diagnostic
sensitivity and specificity of 99.7%, and 97.3% respectively. The APMV-1 nucleocapsid relative
diagnostic sensitivity and specificity were 95.4%, and 98.5% respectively.
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Recent outbreaks of avian influenza (AI) and avian
paramyxovirus-1 (APMV-1) infections in domestic poultry in
Canada, Mexico, China, India, Vietnam, Colombia, Russia, Italy,
Japan, Korea, parts of the Middle East, and parts of Africa, have
led to the destruction of a large number of flocks with a total
economic impact in the millions of dollars (Mutinelli et al.,C-ND license. 
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Watson et al., 2009). From 2006 to 2009, the OIE with its 176
member countries, reported that APMV-1 caused outbreaks
in 56 countries while HPAI caused outbreaks in 28 countries
(World Livestock Disease Atlas, 2011). The highly contagious
nature and similar clinical characteristics of both APMV-1 andAI
infections emphasize the importance of being able to perform
rapid and accurate serologic diagnosis that can determinewhich
disease is causing the outbreak (Alexander and Senne, 2003;
Leijon et al., 2011).
Avian influenza viruses belong to the influenza A genus of
theOrthomyxoviridae family and have a genome that ismade up
of 8 single-stranded RNA segments of negative sense that code
for 11 proteins. They are classified into serological subtypes
based on their viral surface glycoproteins–hemagglutinin (H1 to
H16) and neuraminidase (N1 to N9). Based on their potential to
cause disease in chickens, AIV are divided into low pathogenic
(LPAI) and highly pathogenic (HPAI) viruses. Low pathogenic
AIV causes a localized mild respiratory or enteric disease, while
few viruses belonging to H5 and H7 subtypes are considered
highly pathogenic AIV and cause systemic disease of domestic
poultry with up to 100%mortality. Low pathogenic AI and HPAI
H5 and H7 are both reportable to the OIE.
Newcastle disease virus (NDV) also known as APMV-1
belongs to the family of Paramyxoviridae, genus Avulavirus. The
virus has a single stranded RNA genome of negative sense
containing 6 genes that code for 9 structural and non-structural
proteins. The OIE defines velogenic ND as a virus with an
intracerebral pathogenicity index of N0.7 for day-old chicks, or
with a polybasic cleavage site in the F protein. Newcastle
disease can also be caused by lentogenic strains that cause
sub-clinical to mild clinical disease; mesogenic – causing
non-fatal respiratory disease; and velogenic –most pathogenic
and often fatal (Aldous and Alexander, 2001; Kapczynski et al.,
2013; Seal et al., 2002).
Currently, a variety of serological assays are being used
for the detection of AIV and APMV-1 antibodies in domestic
poultry tomonitor the antibody response due to infection, or
for the purpose of monitoring vaccine efficacy. Although
different commercially available ELISA kits are used for
detecting APMV-1 antibodies in domestic poultry, the HI
assay continues to be the “gold standard” for detecting APMV-1
antibodies. For the detection of AIV antibodies, the agar gel
immunodiffusion (AGID) and hemagglutination inhibition (HI)
test remain as the “gold standard”methods approved by the
OIE. The AGID test detects antibodies against the highly
conserved nucleoprotein (NP) and matrix (M1) proteins.
However, the assay is less sensitive and is prone to producing
higher rates of false negatives (Snyder et al., 1985; Watson et
al., 2009; Zhou et al., 1998). Unlike the AGID test, the HI assay
specifically detects hemagglutinin subtype specific antibodies
using H1–H16 antigens, however it has several drawbacks: it is
labor intensive, difficult to automate as results are read visually,
it requires subtype specific antigens that are difficult to
produce under ordinary lab conditions, the antigens are hard
to standardize as they need to be calibrated for each assay,
and the assay depends on fresh red blood cells (RBC) from
chickens that can be difficult to acquire (Comin et al., 2013;
Upadhyay et al., 2009; Zhou et al., 1998). In addition, the
reference antigen used in the HI assay needs to be updated on a
yearly basis with respect to the currently circulating viruses,otherwise this may impair the sensitivity of the assay
dramatically.
Currently, different laboratories use the HI assay in
combination with an ELISA to check the immune status of
vaccinated flocks (Desvaux et al., 2012; Toffan et al., 2010).
Despite their robustness and higher sensitivity, ELISAs don't
have multiplexing capabilities, and for each individual analyte
to be detected a separate test must be carried out making the
use of ELISAs time consuming and laborious. In the current
study, the development of a duplex florescent microsphere
immunoassay (FMIA) based on the xMAP technology for
simultaneous detection and differentiation of antibody re-
sponse to AIV and APMV-1 infections is described. The duplex
FMIA is based on AIV nucleoprotein (AIV-NP) and APMV-1
nucleocapsid protein (APMV-1-NC) that are the most abun-
dant proteins in AIV and APMV-1 respectively. Both AIV-NP
and APMV-1-NC proteins are highly conserved and immuno-
genic, which therefore makes them suitable candidates for the
detection of virus-specific antibodies and for serologic diagno-
sis of each individual disease.2. Materials and methods
2.1. Cloning of APMV-1 nucleocapsid and AIV nucleoprotein genes
Avian Influenza nucleoprotein from A/Duck/AB/AFLB-C16/
2008 (H7N7) and APMV-1-NC from APMV-1 vaccine (La'Sota)
were selected for the development of the assay. The AIV-NP
gene was amplified using universal AIV-NP primers as
described previously (Hoffmann et al., 2001) and cloned into
PCR4TOPO cloning vector (Invitrogen, Ontario, CA). The coding
region of AIV-NPwas re-amplified using forward primers: ACG
CGC CCG CTA TGG CGT CTC AAG GCG CCA A and reverse
primers: CGG TCT GAG TTAATTGTCATACTC CTC TGCATT. The
full nucleocapsid gene from APMV-1, La'Sota strain was
amplified using primers: ATG TCT TCC GTA TTT GAT GA
(forward) and TCA ATA CCC CCA GTC GGT GT (reverse). The
amplified AIV-NP and APMV-1-NC PCR products were
sub-cloned in-frame into the Not 1 and Xba 1 restriction
enzyme sites of pAB-bee-FH transfer vector which included
an 8X HIS tag for later protein purification (AB Vector,
California). Correct frame and sequence of the gene in the
transfer vector (pAB-bee-FH–APMV-1-NC or AIV-NP) were
confirmed by sequencing.2.2. Transfection and generation of recombinant baculovirus
The APMV-1-NC or AIV-NP genes that were cloned in the
transfer vector were co-transfected into Spodofera frugiperda
(Sf-9) cells with ProFold-ER1 linearized baculovirus DNA
(AB Vector, California, USA). All procedures for the produc-
tion of recombinant proteins, including plaque purification,
production of high titer stocks and optimization of protein
expression were performed according to the manufacturer's
protocols (AB Vector, California, USA). The APMV-1-NC or
AIV-NP recombinant proteins from the cell pellets and media
supernatants were purified by batch procedure using Ni-NTA
agarose (Qiagen, Maryland, USA) according to manufacturer's
instructions.
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Coupling of proteins to Luminex MagPlex Microspheres was
carriedout according to themanufacturer's instructions (Luminex
Corporation, Texas, USA). Prior to coupling, the recombinant
proteins were desalted using micro-biospin 6 columns (Bio-Rad,
California, USA) according to the manufacturer's instructions
to exchange the buffer from imidazole to PBS, and quantified
using Pierce BCA Protein Quantification Kit (Thermo Scientific,
Maryland, USA). Recombinant APMV-1-NC protein were coupled
to MagPlex region #012 microspheres and AIV-NP were coupled
to region #015 (Luminex Corporation, Texas, USA). Twelve
micrograms (μg) of each recombinant protein were coupled to a
fixed amount of beads (1.25 × 106) per 1× reaction.
2.4. Duplex FMIA
Coupled APMV-1-NC and AIV-NP beads at concentration of
2000 beads/well were combined and blocked for 2 h in 5% (v/v)
normal donkey serum (Jackson ImmunoResearch Laboratories
Inc., Pennsylvania, USA) in PBS. Twenty five microliters of bead
suspension and 25 μl of test serum diluted 1:500 in 1% (v/v)
normal donkey serum in PBSwere added to eachwell. The plate
was left at room temperature in the dark on a shaking incubator
for 1 h. A wash program consisting of 3 washes with 200 μl
of PBS-tween 20 in magnetic plate washer was completed
(Bio-Tek, 405 Select TS), and the plates were incubated with
50 μl of 2 μg/ml biotinylated donkey anti-chicken immu-
noglobulin (Jackson ImmunoResearch Laboratories, Inc.,
Pennsylvania, USA) for 30 min at room temperature. Plates
were washed again before the final addition of 75 μl of
10 mg/ml streptavidin-phycoerythrin conjugate (Jackson
ImmunoResearch Laboratories Inc., Pennsylvania, USA) and
incubation at room temperature for 15 min. Following the final
wash, each well of beads were re-suspended in 125 μl of wash
buffer and analyzed with a BioPlex 100 instrument running
Bioplex Manager 6.1 software (Bio-Rad, California, USA). The
results were expressed as arbitrary units of median fluores-
cence intensity (MFI).
2.4.1. Luminex reference curve
A 12-step reference curve was developed for use with
the assay as a method of variability monitoring between
consecutive runs by comparing the changes in fluorescent
signal of the reference curve, and using this data to calculate
a correction factor which was applied to all data sets. The
references were prepared by mixing AIV and APMV-1
hyper-immune sera of known titers and diluted 2-fold in
negative chicken serum to produce a 12-step curve. These
reference samples were tested for the presence of AIV and
APMV-1 antibodies using the IDEXX ELISA kits and hemagglu-
tination inhibition assays. The hemagglutination inhibition
titers of both the APMV-1 and AI sera that were used for
making the standards were 512 and 128 consecutively.
2.4.2. Luminex internal controls
Region 18 and 19 MagPlex beads were used for internal
controls for the assay. Highly purified chicken IgY (Jackson
ImmunoResearch Laboratories, Inc., Pennsylvania, USA) and
donkey anti chicken IgY (Jackson ImmunoResearch Laboratories,
Inc., Pennsylvania, USA) 0.1 μg/ml concentrations each werecoupled to these respective bead regions as described above, and
included in the assay for the purpose of verifying the addition of
secondary detection antibody and test serum respectively.2.5. Hemagglutination inhibition assay
Hemagglutination inhibition (HI) assay was performed
according to the methods described in the OIE manual (OIE
Manual, 2008). For testing the serial bleeds from experimen-
tally inoculated chickens, 4 HA units of homologous virus
was combined with 2-fold serial dilutions of each serum
sample. Chicken red blood cells (0.5% v/v suspension) were
then added and HI endpoints read. Serum HI titre N1:4 was
considered positive.2.6. IDEXX ELISA
Commercial IDEXX AIV and APMV-1 ELISA kits were used to
determine presence of AIV or APMV-1 antibodies in poultry sera.
Depending on the source of the serum, the indirect APMV-1
antibody test kits for turkey and chicken sera were used (IDEXX
Laboratories, Maine, USA). The competitive MultiS-Screen ELISA
Kit was used for AIV antibody detection in turkey and chicken
sera. Both assays were performed according to the
manufacturer's protocols. Results were quantified by read-
ing plates at 650 nm with SpectraMax Plus microplate
reader (Bio-Tek Instruments Inc., Vermont, USA) using
SoftMax Software (Bio-Tek Instruments, Vermont, USA).2.7. Competitive Enzyme-linked Immunosorbent Assay (cELISA)
Competitive ELISA (cELISA) was performed as described
by Yang et al., 2008. Microtiter plates coated with 1 μg of
recombinant baculovirus AIV-NP protein in carbonate buffer
(pH 9.6) at 100 μl/well and plates were incubated 4 °C
overnight. After washing, equal volumes (50 μl) of diluted
test sera (1:5) and hybridoma culture supernatants contain-
ing AIV-NP monoclonal antibody (1:200) were added to the
plates and incubated at 37 °C for 1 h with agitation. Then,
HRP conjugated anti-mouse IgG (Jackson ImmunoResearch
Laboratories Inc., Pennsylvania, USA) was added and incubated
for 1 h at 37 °C with subsequent washing. Lastly, the enzyme
substrate, 3,3′,5,5′-Tetramethylbenzidine (TMB, Sigma-Aldrich,
Missouri, USA), was added and color development was stopped
after 15 min with 50 μl/well of 2.0 M sulfuric acid. The OD
was determined at 450 nm on an automated plate reader
(SpectraMax Plus, Molecular Devices, California, USA).2.8. Serum samples
2462 serum samples that were collected from SPF chickens,
broilers chickens, layers and breeder chickens and an addi-
tional 446 turkey serum samples that were collected from
turkey poults and breeders were used in the validation of the
assay. All sera were pre-screened by a combination of assays
including HI, in-house developed cELISA, and IDEXX ELISA to
determine the presence or absence of detectable antibodies.
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Reference antisera against all existing 16 hemagglutinin
subtypes of AI viruses and avian paramyxovirus (APMV) types
1–9 (Table 1) were produced by inoculating six-week-old
white leghorn specific pathogen free (SPF) chickens that were
obtained from the animal care unit of the Ottawa Laboratory
Fallowfield (OLF), Canadian Food Inspection Agency (CFIA).
The OLF SPF stock was developed from Charles River/SPAFAS
birds (Storrs, Connecticut, USA). Negative SPF chicken sera
used in this study were also collected from the same flock.2.10. Field serum samples
Field serum samples used in this study were collected from
broilers, turkey and chicken breeder flocks; some of which
were vaccinated for APMV-1 using a combination of live and
inactivated APMV-1 vaccines. Some serum samples were
collected from turkeys that were vaccinated with inactivated
H3N4 AIV vaccine (Berhane et al., 2012). Chicken field serum
samples used in this study were donated to us by the Animal
Health Laboratory (AHL), Guelph, Ontario or from archived
serum database of NCFAD.2.11. Production of experimental serum samples
During the production of experimental serum samples, all
animal care and handling procedures were done according
to the Canadian Council on Animal Care guidelines and as
outlined in protocols approved by the institute.Table 1
Reference strains of avian influenza (H1 to H16 subtypes) and avian
paramyxovirus serotype 1–9 (excluding serotype 5)were used for immunizing
specific pathogen free chickens for the production of reference antisera that
was used for the evaluation of the avian influenza and avian paramyxovirus
type 1 duplex FMIA.
Virus type Virus name
H1N1 A/Mallard/ON/6/2005
H2N9 A/Pintail/AB/293
H3N8 A/Duck/UK/1/63
H4N6 A/Duck/BC/14/99
H5N2 A/Turkey/BC/FAV005/2009
H6N2 A/Turkey/MASS/65
H7N2 A/Turkey/Ore/Portchal/75
H8N4 A/Turkey/ON/6118/62
H9N9 A/Pheasant/WA/37349/85
H10N8 A/Turkey/ON/FAV-19/141/2011
H11N9 A/Duck/Memphis/546/74
H12N1 A/Duck/Ab/60/76
H13N1 A/Gull/MD/704/77
H14N5 A/Mallard/Gurjev/263/82
H15N8 A/Duck/Aust/341/83
H16N3 A/BHG/Sweden/5/99/
APMV-1 La'Sota NDV vaccine strain
APMV-2 Chicken/California/Yucaipa/56
APMV-3 Parakeet/Netherlands/449/75
APMV-4 Duck/Hong Kong/D3/75
APMV-6 Duck/Hong Kong/199/77
APMV-7 Dove/Tennessee/4/75
APMV-8 Goose/Delaware/1053/78
APMV-9 Domestic duck/New York/22/782.11.1. Chicken serum
For the production of anti-APMV-1 serum samples, one
group of chickens (n = 20) were inoculated intranasally and
ocularly with 1 ml of inoculum containing 104 egg infective
dose 50 [EID50] of La'Sota APMV-1 vaccine strain. For the
production of AIV serum samples, a second group of chickens
(n = 20) were also inoculated intranasally and ocularly with
1 ml of inoculum containing 104 plaque forming units (PFU)
of low pathogenic influenza virus A/Anhuii/1/2013 (H7N9).
Serum samples were collected at 0, 4, 7, 14, 21 and 28 days
after infection (dpi). The H7N9 group of chickens was kept in
enhanced level 3 animal cubicles
2.11.2. Turkey serum
For experimental turkey serum production, 8 to 10 week
old influenza free turkey poults were bought from a commer-
cial supplier inManitoba. The turkeyswere bled and pre-tested
for the presence of influenza A group specific antibodies (NP)
using cELISA and confirmed negative. The first group of turkeys
(n = 10) were inoculated intranasally and ocularly with
A/turkey/ON/1963 (H6N8), and the second group (n = 10)
with A/turkey/MN/12877/1285/81 (H9N2). The turkeys were
inoculated with 106 egg infectious does50 (EID50)/ml of virus
inoculated intranasally and ocularly. Serum samples were
collected at 0, 7, 14, 21 and 28 days after infection (dpi).
2.12. Data analysis
All statistics were done using the Microsoft Excel add on
“XLSTAT-Life”. Basic frequency versus signal histograms were
generated to visualize the distribution of the data. Receiver
Operating Characteristic analysis (ROC) was used to deter-
mine accurate threshold values for the assay.
3. Results
3.1. Recombinant protein production and puriﬁcation
TheAIV-NP andAPMV-1-NC cloned into pAB-bee-FH transfer
vectors were co-transfected with linearized ProFold™-ER1
baculovirus genomic vector into SF9 cells. The presence
of Aequorea victoria green-fluorescent protein (GFP) in
ProFold™-ER1 allowed for the convenient monitoring of
recombinant baculovirus infection. Expression of both recom-
binant proteins (AIV-NP and APMV-1-NC) in the cell culture
supernatants and cell pellets were monitored by running
the denatured protein product in 10% Bis-Tris precast gels
(Invitrogen) followed by Coomassie blue staining andWestern
blot analysis. The APMV-1-NC or AIV-NP recombinant proteins
from the cell pellets and media supernatants were purified
using Ni-NTA agarose and the purity was confirmed by
SDS-PAGE followed by Coomassie Blue Staining (Fig. 1A) and
the authenticity of the purified recombinant proteins was
confirmed Western blot analysis (Fig. 1B).
3.2. Bead coupling dose response and protocol optimization
The quantity of protein used in each microsphere coupling
reaction was based on recommendations within the Luminex
literature to range from 5 μg to 12 μg of purified protein per 1X
coupling reaction (1.25 × 106 beads per 100 μl reactions). Five
Fig. 1. Analysis of recombinant avian influenza nucleoprotein (2A and 2B)
and avian paramyxovirus-1 nucleocapsid protein (3A and 3B) that were
expressed using the baculovirus expression system were successfully purified
and underwent sodium dodecyl sulfate–polyacrylamide gel electrophoresis
followed by Coomassie Blue staining (Fig. 1A) and western immunoblot
(Fig. 1B) using anti his antibody. Equivalent volumes of each protein (5 μl)
were used for both Coomassie and western immunoblot analysis.
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used to test the different quantities of protein bound to the
beads. Doses of 6 μg, 12 μg, 23 μg, and 45 μg of each recombi-
nant protein were tested in each bead coupling reaction. For
both AIV-NP and APMV-1-NC proteins, coupling with 12 μg of
protein per reaction gave the maximum signal-to-noise ratio
(Fig. 2). The lowest background to noise ratio was achievedFig. 2. The optimization of optimal amount of recombinant protein required for co
Texas, USA) was assessed by testing 4 different concentrations of recombinant avia
(D) with 5 known negative and 6 known positive chicken sera. Beads that were cou
most favorable sample/negative ratio and also displayed the lowest overall backgrowhen the beadswere blocked for 2 h in 5% (v/v) normal donkey
serum in PBS and the test sera diluted at 1:500 in PBS solution
containing 1% (v/v) normal donkey serum.3.3. Assay development
The reference curve developed for monitoring assay
variability between consecutive runs was also used to
demonstrate that the assay was not affected when detecting
antibody with both beads simultaneously. Monoplex and
duplex FMIA results for both AIV-NP and APMV-1-NC were
analyzed using the non-parametric Wilcoxon, Mann–Whit-
ney comparison test with 5% significance level (XLSTAT
2013). Neither result suggested to reject the null hypothesis
(H0: The difference between the samples is equal to 0), so the
monoplex and duplex FMIA results were not found to be
significantly different (AIV-NP p-value 0.865; APMV-1-NC
p-value 0.706). The AIV-NP coated beads were able to detect
antibodies developed against all existing hemagglutinin
subtypes (H1 to H16) while showing no cross reactivity
with antisera developed against APMV 1, 2, 3, 4, 6, 7, 8, and 9
serotypes (Fig. 3). The APMV-1-NC beads did not cross react
with any of the H1 to H16 subtypes of influenza, and were
able to detect antibodies to APMV-1 very strongly. The
APMV-1-NC cross-reacted weakly with anti-sera developed
to APMV-7 and APMV-9 (Fig. 3).
The antibody coupledmicrospheres (chicken IgY and donkey
anti-chicken IgY) were used as internal assay controls to
confirm the addition of critical reagents. The presence of
donkey anti-chicken IgY coupled microspheres ensured that
test serumhas been added. The presence of chicken IgY coupled
microspheres, ensured that the secondary detection antibody
has been added. The presence of these internal controls helped
elucidate false negatives caused by user error. MFI values
greater than 8000 for each internal controlmicrosphere indicate
successful reagent addition.upling to the Luminex MagPlex Microspheres (Luminex Corporation, Austin,
n influenza nucleoprotein at 5.6 μg (A), 11.2 μg (B), 22.4 μg (C) and 44.8 μg
pled with 11.2 μg of recombinant avian influenza nucleoprotein showed the
und signal.
Fig. 3. Fig. 3A & B. Comparison of results of the FMIA using recombinant avian influenza nucleoprotein and avian paramyxovirus type 1 nucleocapsid coated beads
when tested in monoplex and duplex formats with the Luminex reference sera. Fig. 3A describes avian paramyxovirus type 1 FMIA in monoplex and duplex
formats and Fig. 3B— avian influenza monoplex and duplex FMIA. There was no significant difference in fluorescent mean values (MFI) when the assays were run
in duplex or monoplex formats. C. The duplex fluorescent microsphere immunoassay for serologic diagnosis of avian influenza and avian paramyxovirus type 1
infection was tested using a panel of reference antisera against all the existing 16 hemagglutinin subtypes (H1 to H16) and avian paramyxoviruses type 1–9
(excluding type-5). The Luminex beads coated with avian influenza nucleoprotein were able to detect antibodies against all 16 hemagglutinin subtypes and beads
coated with avian paramyxovirus-1 nucleocapsid protein were able to detect reference antisera against type 1 with minimal cross reactivity to type 7 and 9.
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In order to determine the analytical sensitivity of the
assay, AIV and APMV-1 reference antisera that were devel-
oped in chickens were diluted 2-fold in negative SPF chickens
serum (Sigma Aldrich, USA) in a 12-step dilution series. The
APMV-1 reference antiserum was developed in chickens
that were inoculated with La'Sota NDV vaccine strain. The
hemagglutination inhibition titer of this antiserum to homol-
ogous antigen was 512. The AIV reference antiserum was
produced in chickens that were inoculated with A/Chicken/
BC/514/2004 (H7N3) and HI titer of this antiserum toFig. 4. A 12 step 2-fold serial dilutions of reference AI and APMV-1 sera were cond
beads were able to detect dilution of antisera at 1/128, and APMV-1-NC beads werhomologous antigen was 256. These 12 serial dilutions OF
AIV and APMV-1 antisera were tested using the AIV-NP and
APMV-1-NC duplex FMIA. The AIV-NP beads were able to
detect antibodies in serum at dilutions as low as 1/128, and
APMV-1-NC beads could detect antibodies at dilutions as
low as 1/1024 before falling below the assay background
(Fig. 4).
3.5. Statistical normalization of results
The standard curve results were compiled for every run of
the FMIA, providing a summary of how the assay performeducted to determine the analytical sensitivity of the duplex FMIA. The AIV-NP
e able to detect down to 1/1024.
173M.M. Pinette et al. / Journal of Immunological Methods 405 (2014) 167–177over time. Statistical ANOVA testing was carried out across the
individual reference controls and revealed a minor difference
between runs. This prompted the normalization of the overall
data to correct for assay variation. Averages of the MFI values
of each standard were calculated across all runs and the
calculated averages of the standards were used to generate an
overall correction factor to determine the correct assay values.
When values of the standards were higher or lower than the
average, the entire standard curve usually reflected this shift
eitherwholly above, orwholly below the average. For example,
if standard 1 read a greater value than normal, the rest of the
reference samples in that run also read greater values than
normal. This allowed us to create a separate correction factor
for each run of the assay and apply it uniformly to either raise
or lower the observed values to normalize the values of the
standard curve. The corrected assay values were then used for
statistical analysis to determine the assay cut-off.
3.6. Receiver operating characteristic analysis for threshold
determination
Receiver operating characteristic (ROC) analysis was used
for assay threshold determination because of the inability to
transform the data to fit a normal distribution even after
attempted log10 and fourth root transformations (Fig. 5). The
ROC analysis was used to calculate the threshold value
determined by the ratio of true positives to false negatives.
The median fluorescence intensity (MFI) at which the ratio of
false positives and false negatives are lowest determines theFig. 5. Figures describe the combined frequency distribution of all chicken and turke
negative samples. A) Avian paramyxovirus 1 negative serum samples; B) Avian para
samples; D) Avian influenza positive serum samples.optimal threshold. The IDEXX ELISA results were used as a
guide for “true positive” and “true negative” status of the test
serum undergoing analysis as the assay has been commer-
cially validated. The diagnostic specificity of the APMV-1
IDEXX ELISA was 100% (n = 40 SPF sera), and the assay
showed sensitivity of 91.5% in relation to HI results (n = 47)
(IDEXX APMV-1 ELISA Validation Report 2010). The AIV
MultiS-Screen ELISA has a diagnostic specificity of 99.7%
(n = 5007), and diagnostic sensitivity that matched the HI
(IDEXX AIV ELISA Validation Report). In the events where the
IDEXX ELISA and the HI results were in disagreement, “true
positivity or negativity”was assigned according to the HI as it
is the current gold standard and also the assay that the IDEXX
was validated against.
The AIV antibody response detection threshold of the
duplex FMIA was calculated to be 1835 median fluorescent
units with an associated diagnostic sensitivity of 99.7% and
diagnostic specificity of 97.3% relative to the IDEXX ELISA.
This threshold value yielded 332 relative true positives, 56
false positives, 1 false negative, and 1987 true negatives.
The avian paramyxovirus antibody response detection
threshold of the duplex FMIA was calculated to be 2284
median fluorescent units (MFU) with an associated diagnos-
tic sensitivity of 95.4% and diagnostic specificity of 98.5%
relative to the IDEXX ELISA. This threshold yielded 313 true
positives, 18 false positives, 15 false negatives, and 1149 true
negatives.
All values were statistically significant within a 95%
confidence interval (XLSTAT 2013).y serum data for threshold determination, separately analyzing positive and
myxovirus type 1 positive serum samples; C) Avian influenza negative serum
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duplex FMIA
3.7.1. Chickens
The duplex FMIA was used to monitor the kinetics of
antibody responses in 2 groups of chickens that were
experimentally infected with influenza and APMV-1 La'Sota
strain. Serum samples that were collected at 0, 4, 7, 14, 21
and 28 days after infection (dpi) were tested using the
duplex FMIA. In addition, the serum samples were also tested
for the presence of APMV-1 antibodies using the indirect
IDEXX APMV-1 ELISA kit and HI assay. In addition to the
FMIA, for detecting AIV antibodies the IDEXX AIVMultiscreen
ELISA Kit was also used. All pre-bleed samples from chickens of
both groups tested negative for AIV and APMV-1 antibodies
using all test methods.
Chickens that were infected with APMV-1 started to
develop antibody responses at 7 dpi and reached peak MFU
by 14 dpi. The results were comparable to APMV-1 IDEXX
ELISA results, but the duplex FMIA was more sensitive than
HI assay. Results of this study are summarized in Fig. 6A.
Serum samples collected from the 2nd group of chickens
that were infected with A/Anhuii/1/2013 (H7N9) were tested
on the duplex FMIA. Infected chickens started to develop
antibody responses starting at 4 dpi based on the IDEXX
ELISA and duplex FMIA results. By 7 dpi, all samples tested
positive on the IDEXX ELISA and duplex FMIA. However,
there were only 3 samples that were positive on the HI assay.
At 14 dpi, all samples tested positive on the IDEXX ELISA andFig. 6. 6A). Kinetics of antibody response in chickens that were immunized with ND
Laboratories, Maine, USA) and hemagglutination inhibition assay using homologo
sero-convert by 7 dpi according to the duplex assay and IDEXX ELISA. 6B) Kinetics of
(H7N9) using the duplex FMIA, avian influenza Multiscreen ELISA Kit (IDEXX Labora
antigen. 100% of chickens were able to sero-convert by 7 dpi according to the duplon the duplex FMIA, however only 50% of samples had anti
H7 hemagglutinin antibodies. By 21 dpi, all assays were
detecting a positive immune response from all test serum.
Results of this study are summarized in Fig. 6B.
3.7.2. Turkeys
The duplex FMIA assay was also used to detect the kinetics
of antibody responses in turkey poults that were infected with
LPAI viruses. For this purpose, turkeys in the 1st group were
inoculated with A/turkey/ON/1963 (H6N8), and the 2nd group
with A/turkey/MN/12877/1285/81 (H9N2). Pre-bleed serum
samples collected from these turkeys tested negative for
APMV-1 and AIV antibodies using the FMIA or IDEXX ELISA
tests for both antibodies. Based on the IDEXX ELISA and FMIA
results, almost 100% of the turkeys in both groups elicited
humoral immune response against AIV starting at 7 dpi and
reached peak responses by 14 dpi. According to the HI assay
results, anti-hemagglutinin antibodies were detected in the
90% of turkeys in the H9N2 group by 14 dpi and all turkeys
seroconverted by 21 dpi and remained at higher level until the
end of the study at 28 dpi. Sixty percent of turkeys that were
inoculated with the H6N8 virus developed anti hemagglutinin
antibodies at 14 and 21 dpi. Results of this study are
summarized in Fig. 7.
4. Discussion
The most commonly used serological methods of diagno-
sis to detect antibody response to APMV-1 and AIV infectionsV La'Sota vaccine strain using the duplex FMIA, NDV IDEXX ELISA kit (IDEXX
us La'Sota antigen. According the FMIA data, 100% of chickens were able to
antibody response in chickens that were infected with LPAI A/Anhuii/1/2013
tories, Maine, USA) and hemagglutination inhibition assay with homologous
ex assay and the IDEXX ELISA.
Fig. 7. Kinetics of antibody response in turkeys that were infected with either LPAI A/turkey/MN/12877/1285/81 (H9N2) (7A) or A/turkey/ON/1963 (H6N8) (7B)
using the duplex FMIA, avian influenza Multiscreen ELISA Kit (IDEXX Laboratories, Maine, USA) and hemagglutination inhibition assay using corresponding
homologous antigens. Almost 100% of turkeys were able to sero-convert by 7 dpi according to the duplex assay and the IDEXX ELISA.
175M.M. Pinette et al. / Journal of Immunological Methods 405 (2014) 167–177in domestic poultry are by ELISA and HI assay; in addition the
AGID test is used for detecting AIV antibodies. Although AGID
and HI are gold standards, both assays are labor intensive and
are less suited for high-throughput screening. The current
project reports the development of multiplex immunoassay
with the ability to simultaneously detect antibody responses
to AIV and APMV-1 infections using the Luminex xMAP
Technology.
The application of Luminex technology for the detection
of antibody responses to multiple pathogens in a single assay
format has been demonstrated previously (Anderson et al.,
2011; Bergmann et al., 2003; Chen et al., 2009; Clavijo et al.,
2006; Dias et al., 2005; Lupiani et al., 2010; Martins, 2002).
Most of these developed assays used either recombinantly
expressed proteins, or purified, or semi-purified antigens
coupled to the beads. In the current study, expression of the
AIV-NP and APMV-1-NC proteins were by using the baculovirus
expression system. Producing the recombinant antigens in
the baculovirus expression system has significant advantages
including accurate glycosylation, speed and volume of protein
expression, as well as proper folding (Invitrogen, Ontario, CA).
Expressing the recombinant proteins fused to a His-tag had
additional advantages in attaining a very clean protein product
that helpedminimize the occurrence of possible cross-reactions,
lowered unwanted background signal in the assay, and also
increased confidence of the results.
Many veterinary diagnostic laboratories currently use the
IDEXX ELISA or other similar ELISAs for serologic screening of
both AIV and APMV-1 disease infections in domestic poultry.
The performance of the duplex FMIA was compared to the
widely used IDEXX ELISA kits for both infections. In addition,
for detecting AIV antibodies an in-house developed cELISA
was used which employed identical capture antigen that was
used in the FMIA (data not shown). Based on the comparativedata presented in this study, the duplex FMIA assay perfor-
mance was almost identical to the IDEXX ELISA kits for both
diseases. Although the IDEXX ELISA kits or other commercially
available ELISA kits allow for the processing of a very large
number of samples in a relatively short period of time, they lack
the multiplexing capabilities, and individual tests have to be
carried out for each analyte to be detected. Therefore, ELISA
testing becomes laborious and time consuming. The duplex
FMIA reported here has a number of advantages as it is able to
detect antibody responses to AIV and APMV-1 infection using a
single serum dilution and also could easily be automated and
used for processing of large amounts of serum submissions.
The assay's potential to detect multiple targets in the same
platform could offer substantial benefits for routine serological
testing through reduced staff and reagent costs, and simplified
laboratory operation.
As described previously by Martins (2002), the duplex
FMIA assay also incorporates an additional two microspheres
as internal controls that allow for the establishment of quality
control parameters to ensure that each individual reaction has
received the correct reagents. This allows the monitoring of
whether the correct concentration of each individual reagent
such as test sera, conjugate, and substrate has been added. The
secondary antibody addition control ranged in from 9000 to
12,000 MFI on average. MFI values below 8000 were consid-
ered untrustworthy and repeated. The control for proper
serum addition ranged from 6000 to 10,000 MFI on average.
MFI values below 6000 were considered unreliable and were
retested. Internal controls were tested on plates where serum
or secondary antibody were intentionally left out or added
incorrectly, and the controls successfully identified all prob-
lematic wells. Internal controls could also be utilized to increase
precision and accuracy by monitoring instrument fluctuations,
allowing intra- and inter-assay normalization (Martins, 2002).
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compared with IDEXX ELISA kits in studying the kinetics
of immune responses in chickens and turkeys that were
infected with different subtypes of LPAI viruses. Based on
these studies, in most infected animals, AIV antibodies could
be detected as early as 4–7 dpi; reaching their peak by 14 dpi
and remaining at a high level until 28 dpi. The results of
duplex FMIA were almost identical to the IDEXX ELISA kit
values for most of the groups infected with different subtypes
of AIV. In addition, the performance of the assay was almost
identical to the commercial ELISA platform when studying
the kinetics of antibody responses in chickens immunized
with the La'Sota APMV-1 vaccine. Antibodies to ND-NC could
be detected as early as 4–7 dpi and remained at peak levels
until 28 dpi. This study demonstrates the usefulness of the
assay in monitoring antibody response in chickens or turkeys
that were exposed to APMV-1 and AIV. The assay was also
useful in monitoring antibodies in field serum samples
collected from turkey breeders immunized with inactivated
AIV and APMV-1.
The stability of AIV-NP andAPMV-1-NC coupled beads stored
at 4 °C was tested for a period of 4 months. The reference curve
was used as a benchmark to track the sensitivity of the assay for
this period of time, and four month old protein coupled beads
have yet to showa drop in fluorescence values (data not shown).
In the duplex FMIA assay, there was limited cross reactivity
between the APMV-1-NC antigen with APMV-7 and APMV-9
antisera. There is a possibility that this could be due to the
presence of some conserved immunogenic antigenic sites
on the nucleocapsid protein between these viruses and
APMV-1 serotypes. Traditionally, APMVs are grouped into
different serotypes (APMV-1 to AMPV-9) based on the HI
test (Alexander, 1988), however, antibodies to prototype
viruses representative of the nine currently defined APMV
serotypes are already known to cross react with other APMV
serotypes and with mammalian paramyxoviruses (Alexander
and Chettle, 1978; Alexander and Collins, 1981; Kessler et al.,
1979; Lipkind et al., 1982; Shortridge et al., 1980; Tumova et al.,
1979). It is possible the APMV-1-NC may be too conserved
among APMV serotypes to provide enough resolution for the
exact classification.
A number of Luminex based assays have been developed for
serologic diagnosis of avian diseases including AIV (Chowdhury
et al., 2009; Drummond et al., 2008; Giavedoni, 2005; van
Gageldonk et al., 2008; de Jager et al., 2005). To our knowledge
this is the first study where a duplex FMIAwas developed for
serologic diagnosis and differentiation of two important
poultry diseases. The time saving value of the FMIA even
makes it a feasible option for high-throughput surveillance
testing (Seideman and Peritt, 2002).
Receiver Operating Characteristic analysis (ROC) is a
statistical non-parametric function that was used to determine
the assay threshold values by analyzing the trade-off between
true positive results and false positive results (Fawcett, 2006).
Overall performance of the assay is consistent, and is based on a
large data set. It is important to include a set of reference
standards to allow for independent threshold determination
without the need to normalize results. However, if the assay
were to only be used with chicken and turkey serum from the
same geographical region, once a suitable threshold value has
been determined, there is no need to undergo the complexstatistical analysis again. In its current state, the assay could be
effectively used for surveillance of AIV and APMV-1 in poultry
flocks. New work is under way to incorporate two additional
bead sets whichwill allow for the specific differentiation of AIV
infections of H5 or H7 subtypes. These are the notifiable forms
of AIV and also have the capacity to become highly pathogenic
strains.
Acknowledgments
The project was funded by CFIA (WIN-A-1304), Manitoba
Egg Producers and MAFRI (Manitoba Agriculture, Food and
Rural Initiatives). The authors would like to acknowledge Dr.
Kathleen Hooper McGreevy and Animal Health Laboratory
(AHL), Guelph, ON for providing the field sera used in the
studies, Dr. Kurtis Swelka and his animal care staff for helping
out with animal experiments, Dr. Andre Broes (Bio-Vet) for
his input in assay development, and Dr. Gary Crow for his
statistical analysis advice. CSF/Avian staff and Kate Hole for
their help in some aspects of the assay validation.
References
Aldous, E.W., Alexander, D.J., 2001. Detection and differentiation of Newcastle
disease virus (avian paramyxovirus type 1). Avian Pathol. 30, 117.
Alexander, D.J., 1988. Newcastle disease virus — an avian paramyxovirus. In:
Alexander, D.J. (Ed.), Newcastle Disease. Kluwer Academic Publishers,
Boston, MA, p. 11.
Alexander, D.J., Chettle, N.J., 1978. Relationship of parakeet/Netherlands/
449/75 virus to other avian paramyxoviruses. Res. Vet. Sci. 25 (1), 105.
Alexander, D.J., Collins, M.S., 1981. The structural polypeptides of avian
paramyxoviruses. Arch. Virol. 67 (4), 309.
Alexander, D.J., Senne, D.A., 2003. Newcastle disease, other avian paramyxo-
viruses and pneumovirus infections: Newcastle disease, other avian
paramyxoviruses, In: Saif, Y.M. (Ed.), Diseases of Poultry, 7th edn. Iowa
State University Press, Ames, p. 63.
Anderson, S., Wakeley, P., Wibberley, G., Webster, K., Sawyer, J., 2011.
Development and evaluation of a Luminex multiplex serology assay to
detect antibodies to bovine herpes virus 1, parainfluenza 3 virus,
bovine viral diarrhoea virus, and bovine respiratory syncytial virus,
with comparison to existing ELISA detection methods. J. Immunol.
Methods 366, 79.
Bergmann, I.E., Neitzert, E., Malirat, V., Ortiz, S., Colling, A., Sanchez, C.,
Correa Melo, E., 2003. Rapid serological profiling by enzyme-linked
immunosorbent assay and its use as an epidemiological indicator of
foot-and-mouth disease viral activity. Arch. Virol. 148, 891.
Berhane, Y., Kehler, H., Handel, K., Hisanaga, T., Xu, W., Ojkic, D., Pasick, J.,
2012. Molecular and antigenic characterization of reassortant H3N2
viruses from turkeys with a unique constellation of pandemic H1N1
internal genes. PLoS One 7 (3), e32858.
Chen, T., Lee, F., Lin, Y., Pan, C., Shih, C., Lee, M., Tsai, H., 2009. Development of
a Luminex assay for the detection of swine antibodies to non-structural
proteins of foot-and-mouth disease virus. J. Immunol. Methods 396,
87–95.
Chowdhury, F., Williams, A., Johnson, P., 2009. Validation and comparison of
two multiplex technologies, Luminex® and Mesoscale Discovery, for
human cytokine profiling. J. Immunol. Methods 340, 55.
Clavijo, A., Hole, K., Li, M., Collingnon, B., 2006. Simultaneous detection of
antibodies to foot-and-mouth disease non-structural proteins 3ABC, 3D,
3A and 3B by a multiplexed Luminex assay to differentiate infected from
vaccinated cattle. Vaccine 24, 1693.
Comin, A., Toft, N., Stegeman, A., Klinkenberg, D., Marangon, S., 2013. Serological
diagnosis of avian influenza in poultry: is the haemagglutination inhibition
test really the ‘gold standard’? Influenza Other Respi. Viruses 7, 257.
de Jager, W., Prakken, B.J., Bijlsma, J.W.J., Kuis, W., Rijkers, G.T., 2005.
Improved multiplex immunoassay performance in human plasma and
synovial fluid following removal of interfering heterophilic antibodies.
J. Immunol. Methods 300, 124.
Desvaux, S., Garcia, J.M., Nguyen, T.D., Reid, S.A., Bui, N.A., Roger, F., Fenwick,
S., Peiris, J.S., Ellis, T., 2012. Evaluation of serological tests for H5N1
avian influenza on field samples from domestic poultry populations in
Vietnam: consequences for surveillance. Vet. Microbiol. 156, 277.
177M.M. Pinette et al. / Journal of Immunological Methods 405 (2014) 167–177Dias, D., Van Doren, J., Schlottmann, S., Kelly, S., Puchalski, D., Ruiz, W.,
Boerckel, P., Kessler, J., Antonello, J.M., Green, T., Brown, M., Smith, J.,
Chirmule, N., Barr, E., Jansen, K.U., Esser, M.T., 2005. Optimization and
validation of a multiplexed Luminex assay to quantify antibodies to
neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18. Clin.
Diagn. Lab. Immunol. 12, 959.
Drummond, J.E., Shaw, E.E., Antonello, J.M., Green, T., Page, G.J., Motley, C.O.,
Wilson, K.A., Finnefrock, A.C., Liang, X., Casimiro, D.R., 2008. Design and
optimization of amultiplex anti-influenza peptide immunoassay. J. Immunol.
Methods 334, 11.
Fawcett, T., 2006. An introduction to ROC analysis. Pattern Recogn. Lett. 861.
Giavedoni, L.D., 2005. Simultaneous detection of multiple cytokines and
chemokines from nonhuman primates using Luminex technology.
J. Immunol. Methods 301, 89.
Hoffmann, E., Stech, J., Guan, Y., Webster, R.G., Perez, D.R., 2001. Universal
primer set for the full-length amplification of all influenza A viruses.
Arch. Virol. 146, 2275.
Kapczynski, D.R., Afonso, C.L., Miller, P.J., 2013. Immune responses of poultry
to Newcastle disease virus. Dev. Comp. Immunol. 41 (3), 447.
Kessler, N., Aymard, M., Calvet, A., 1979. Study of a new strain of paramyxovi-
ruses isolated from wild ducks: antigenic and biological properties. J. Gen.
Virol. 43, 273.
Leijon, M., Ullman, K., Thyselius, S., Zohari, S., Pedersen, J.C., Hanna, A.,
Mahmood, S., Banks, J., Slomka, M.J., Belak, S., 2011. Rapid PCR-based
molecular pathotyping of H5 and H7 avian influenza viruses. J. Clin.
Microbiol. 49, 3860.
Lipkind, M., Weisman, Y., Shihmanter, E., Shoham, D., 1982. Isolation of yucaipa-
like avian paramyxovirus from a wild mallard duck (Anas platyrhinchos)
wintering in Israel. Vet. Rec. 110 (1), 15.
Lupiani, B., Mozisek, B., Mason, P.W., Lamichhane, C., Reddy, S.M., 2010.
Simultaneous detection of avian influenza virus NP and H5 antibodies in
chicken sera using a fluorescence microsphere immunoassay. Avian Dis.
54, 668.
Martins, T.B., 2002. Development of internal controls for the Luminex
instrument as part of a multiplex seven-analyte viral respiratory antibody
profile. Clin. Diagn. Lab. Immunol. 9, 41.
Mutinelli, F., Capua, I., Terregino, C., Cattoli, G., 2003. Clinical, gross, and
microscopic findings in different avian species naturally infected during
the H7N1 low- and high-pathogenicity avian influenza epidemics in
Italy during 1999 and 2000. Avian Dis. 47, 844.
Pasick, J., Pedersen, J., Hernandez, M.S., 2012. Avian influenza in North
America, 2009–2011. Avian Dis. 56, 845.
Pawar, S.D., Kale, S.D., Rawankar, A.S., Koratkar, S.S., Raut, C.G., Pande, S.A.,
Mullick, J., Mishra, A.C., 2012. Avian influenza surveillance reveals
presence of low pathogenic avian influenza viruses in poultry during
2009–2011 in the West Bengal State, India. Virol. J. 9 (151-422X-9-151).Seal, B.S., Crawford, J.M., Sellers, H.S., Locke, D.P., King, D.J., 2002. Nucleotide
sequence analysis of the Newcastle disease virus nucleocapsid protein
gene and phylogenetic relationships among the Paramyxoviridae. Virus
Res. 83, 119.
Seideman, J., Peritt, D., 2002. A novel monoclonal antibody screening method
using the Luminex-100™ microsphere system. J. Immunol. Methods
267, 165.
Shortridge, K.F., Alexander, D.J., Collins, M.S., 1980. Isolation and properties
of viruses from poultry in Hong Kong which represent a new (sixth)
distinct group of avian paramyxoviruses. Res. Vet. Sci. 255.
Snyder, D.B., Marquardt, W.W., Yancey, F.S., Savage, P.K., 1985. An enzyme-
linked immunosorbent assay for the detection of antibody against avian
influenza virus. Avian Dis. 29, 136.
Toffan, A., Olivier, A., Mancin,M., Tuttoilmondo, V., Facco, D., Capua, I., Terregino,
C., 2010. Evaluation of different serological tests for the detection of
antibodies against highly pathogenic avian influenza in experimentally
infected ostriches (Struthio camelus). Avian Pathol. 39, 11.
Tumova, B., Robinson, J.H., Easterday, B.C., 1979. A hitherto unreported
paramyxovirus of turkeys. Res. Vet. Sci. 135.
Upadhyay, C., Ammayappan, A., Vakharia, V.N., 2009. Detection of NP, N3
and N7 antibodies to avian influenza virus by indirect ELISA using yeast-
expressed antigens. Virol. J. 6 (158-422X-6-158).
van Gageldonk, P.G.M., van Schaijk, F.G., van der Klis, F.R., Berbers, G.A.M.,
2008. Development and validation of a multiplex immunoassay for the
simultaneous determination of serum antibodies to Bordetella pertussis,
diphtheria and tetanus. J. Immunol. Methods 335, 79.
Wang, L., Pan, C., Severinghaus, L.L., Liu, L., Chen, C., Pu, C., Huang, D., Lir, J.,
Chin, S., Cheng, M., Lee, S., Want, C., 2008. Simultaneous detection and
differentiation of Newcastle disease and avian influenza viruses using
oligonucleotide microarrays. Vet. Microbiol. 127, 217.
Watson, D.S., Reddy, S.M., Brahmakshatriya, V., Lupiani, B., 2009. Amultiplexed
immunoassay for detection of antibodies against avian influenza virus.
J. Immunol. Methods 340, 123.
World Livestock Disease Atlas, Bank, W., 2011. A Quantitative Analysis of
Global Animal Health Data. (2006-2009). Washington, DC. http://www.
oie.int/doc/ged/D11291.pdf. Accessed February 24, 2014. p35, 39.
World Organization for Animal Health, 2008. Manual of diagnostic tests and
vaccines for terrestrial animals, Sixth edition. OIE, Paris, France.
XLSTAT, Addinsoft, 2013. Data Analysis and Statistics with MS Excel.
Addinsoft, NY, USA.
Yang, M., Berhane, Y., Salo, T., Li, M., Hole, K., Clavijo, A., 2008. Development
and application of monoclonal antibodies against avian influenza virus
nucleoprotein. J. Virol. Methods 147 (2), 265.
Zhou, E.M., Chan, M., Heckert, R.A., Riva, J., Cantin, M.F., 1998. Evaluation of a
competitive ELISA for detection of antibodies against avian influenza
virus nucleoprotein. Avian Dis. 42, 517.
